

## LISTING OF CLAIMS

1. (Previously Presented) A purified preparation of a glycosylated CD44 polypeptide, said glycosylated CD44 polypeptide comprising an amino acid sequence encoded by a nucleotide sequence comprising exons 1-5, 16, 17, 18, and 20 of a human CD44 gene, wherein the CD44 polypeptide is CD44H, wherein said glycosylated CD44 polypeptide comprises sialylated, fucosylated glycans, wherein said glycosylated CD44 polypeptide is a ligand for E-selectin, L-selectin, or both, and wherein the preparation comprises less than 5% of a polypeptide other than the glycosylated CD44 polypeptide.

2. (Previously Presented) The preparation of claim 1, wherein binding of said glycosylated polypeptide to a HECA 452 antibody decreases following contacting of said glycosylated polypeptide with N-glycosidase-F under conditions sufficient to remove carbohydrate moieties from said glycosylated polypeptide.

3. (Previously Presented) The preparation of claim 1, wherein binding of said glycosylated polypeptide to a HECA 452 antibody decreases following contacting of said glycosylated polypeptide with sialidase under conditions sufficient to remove sialic acid moieties from said glycosylated polypeptide.

4. (Previously Presented) The preparation of claim 1, wherein binding of said glycosylated polypeptide to a HECA 452 antibody decreases following contacting of said glycosylated polypeptide with fucosidase under conditions sufficient to remove fucose moieties from said glycosylated polypeptide.

5. – 6. (Canceled)

7. (Previously Presented) A purified preparation of a glycosylated polypeptide comprising the amino acid sequences of SEQ ID NO: 1, wherein said glycosylated polypeptide comprises sialylated, fucosylated glycans, wherein said glycosylated CD44 polypeptide is a

ligand for E-selectin, L-selectin, or both and wherein the preparation comprises less than 5% of a polypeptide other than the glycosylated polypeptide.

8. - 65. (Canceled)